Neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System Neuspera Medical, Inc. announced on Thursday that it has named Bunty Banerjee as its first chief operating officer.
In the new role, Banerjee is to head activities in both R&D and operations, while working closely with all other functions, as Neuspera completes the US Food and Drug Administration (FDA) submission for regulatory approval of the Neuspera System to treat OAB symptoms and prepares for commercialisation.
Banerjee, a life sciences executive, has over 25 years of experience in the medical device industry, holding senior operational leadership positions at Omnicell, Philips Image Guided Therapy, Abbott and Boston Scientific. He has worked in senior leadership roles in enterprises ranging from early start-ups to Fortune 100 corporations.
Steffen Hovard, CEO of Neuspera Medical, said, 'Bunty is joining Neuspera at an incredibly exciting time for the company. We look forward to his contributions to the team as he deploys valuable skills and insights with the organisation.'
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition